BMO Capital Downgrades Biogen (BIIB) to Market Perform

Baird Downgrades Biogen (BIIB) to Neutral; Diminished Growth Prospects

July 27, 2015 6:35 AM EDT

Baird downgraded Biogen (NASDAQ: BIIB) from Outperform to Neutral with a price target of $316.00 (from $480.00), saying lackluster sales and lowered guidance leaves a growth void.

Analyst Brian Skorney commented, "We're aware that this downgrade may be too little, too late given... More

Biogen's (BIIB) Decline Seen as 'Overreaction' at Deutsche Bank

July 24, 2015 3:36 PM EDT

Deutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $460. Shares declined after Biogen reported Q2 results and cut full-year guidance. In the view of analyst Robyn Karnauskas, the decline was an "overreaction," though she agrees with sentiment.

"The disappointing run of BIIB continued in Q215 as the co substantially revised 2015 FY guidance due to weaker outlook for Tecfidera.... More

Biogen (BIIB) Trading at 'Pharma-Like' Multiple, Cowen Says

July 24, 2015 1:04 PM EDT

Cowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly 20% on disappointing Q2 results and outlook. Schmidt maintained his bullish view, saying the stock is trading at a 'pharma-like' multiple.

Schmidt commented,... More

Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel Says

July 24, 2015 12:19 PM EDT

Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) following disappointing Q2 results, which has shares down 18.4% intra-day. While retaining his Hold rating, the analyst said the stock is worth a hard look when the smoke clears.

Shrader commented, "Biogens numbers were... More

Slowing Tecfidera Sales Increases Biogen's (BIIB) M&A Risk - Moody's

July 24, 2015 11:55 AM EDT

Moody's Investors Service commented that slowing sales of Tecfidera, the largest product of Biogen (NASDAQ: BIIB) increases the event risk of acquisitions. That said, there is currently no effect on Biogen's Baa1 senior unsecured rating or stable rating outlook based on strong financial flexibility.

... More

Biogen (BIIB) Tops Q2 EPS by 12c; Cuts FY15 Revenue Growth, EPS Outlook

July 24, 2015 6:50 AM EDT

(Updated - July 24, 2015 6:51 AM EDT)

Biogen (Nasdaq: BIIB) reported Q2 adjusted EPS of $4.22, which was $0.12 better than the analyst estimate of $4.10. Revenue for the quarter came in at $2.59 billion versus the consensus estimate of $2.71 billion.

Neurology Highlights

In April 2015, the U.S. Food and Drug Administration accepted for review the Biologics License Application for ZINBRYTA for the treatment of relapsing forms of multiple sclerosis. ZINBRYTA is being jointly developed by Biogen and... More